Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E20.56 EPS (ttm)2.74 Insider Own0.20% Shs Outstand1.64B Perf Week-0.55%
Market Cap92.75B Forward P/E17.80 EPS next Y3.17 Insider Trans-4.93% Shs Float1.64B Perf Month1.77%
Income4.59B PEG2.43 EPS next Q0.76 Inst Own71.20% Short Float0.54% Perf Quarter4.44%
Sales20.24B P/S4.58 EPS this Y184.60% Inst Trans-0.64% Short Ratio1.19 Perf Half Y3.35%
Book/sh8.94 P/B6.31 EPS next Y6.70% ROA13.70% Target Price57.32 Perf Year-3.85%
Cash/sh3.96 P/C14.26 EPS next 5Y8.47% ROE30.10% 52W Range46.01 - 60.45 Perf YTD-3.46%
Dividend1.56 P/FCF63.97 EPS past 5Y4.20% ROI19.80% 52W High-6.67% Beta1.18
Dividend %2.76% Quick Ratio1.50 Sales past 5Y-1.80% Gross Margin73.50% 52W Low22.63% ATR0.95
Employees25000 Current Ratio1.60 Sales Q/Q5.60% Oper. Margin29.50% RSI (14)50.32 Volatility1.28% 1.75%
OptionableYes Debt/Eq0.56 EPS Q/Q-20.10% Profit Margin22.70% Rel Volume0.65 Prev Close56.77
ShortableYes LT Debt/Eq0.47 EarningsJul 27 BMO Payout55.80% Avg Volume7.39M Price56.42
Recom2.40 SMA200.21% SMA501.27% SMA2002.18% Volume4,798,985 Change-0.62%
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Apr-06-16Initiated Societe Generale Sell $48
Jan-22-16Upgrade Berenberg Hold → Buy
Dec-02-15Upgrade Guggenheim Neutral → Buy
Dec-01-15Reiterated Barclays Equal Weight $55 → $70
Aug-24-15Upgrade Piper Jaffray Underweight → Neutral
Jun-17-15Initiated Piper Jaffray Underweight $60
May-14-15Initiated Berenberg Hold $70
Apr-21-15Upgrade Morgan Stanley Equal-Weight → Overweight $60 → $80
Feb-27-15Reiterated Argus Buy $70 → $78
Jan-12-15Reiterated Argus Buy $62 → $70
Aug-18-17 10:38AM  Opdivo Could Drive Bristol-Myers Squibbs Revenue Growth in 2017 Market Realist
09:08AM  Chart in Focus: Bristol-Myers Squibbs Performance in 2Q17 Market Realist
07:39AM  Analysts Recommendations for Bristol-Myers Squibb in August 2017 Market Realist
07:09AM  Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo Zacks
06:59AM  Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017 Business Wire
Aug-17-17 05:59PM  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx Zacks
Aug-16-17 03:31PM  [$$] Bristol-Myers Can Overcome Market's Pessimism Barrons.com
11:59AM  Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive' Benzinga
10:53AM  Cramer: Investors Can't Get Enough of Bristol-Myers Despite Latest Drug Setback TheStreet.com
10:03AM  Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214 Zacks
09:45AM  Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis TheStreet.com
09:30AM  Bristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails TheStreet.com
09:25AM  Stocks to Watch: Target, Apple, Amazon, Urban Outfitters, Bristol-Myers The Wall Street Journal
Aug-15-17 04:55PM  Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal MarketWatch
04:51PM  Bristol-Myers kidney cancer drug fails late-stage trial Reuters
04:30PM  Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
11:17AM  3 Big Stock Charts for Tuesday: Bristol-Myers Squibb Co (BMY), United Parcel Service, Inc. (UPS) and Intuit Inc. (INTU) InvestorPlace
Aug-14-17 02:20PM  What Trump has done to lower the RIPOFF DRUG PRICES hes decrying Yahoo Finance
Aug-13-17 03:46AM  Edited Transcript of BMY earnings conference call or presentation 27-Jul-17 2:30pm GMT Thomson Reuters StreetEvents
Aug-12-17 08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Aug-11-17 05:02PM  ETFs with exposure to Bristol-Myers Squibb Co. : August 11, 2017 Capital Cube
03:59PM  Pfizers Valuation after 2Q17 Earnings Market Realist
09:06AM  Luspatercept: Opportunity for Celgenes Long-Term Growth? Market Realist
08:01AM  See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co. Markit
Aug-10-17 08:01AM  IHS Markit Score Update: Drop in demand for ETFs holding Bristol-Myers Squibb Co is a negative sign for its shares Markit
07:37AM  How Celgenes Pomalyst Is Positioned after 2Q17 Market Realist
Aug-09-17 02:36PM  How Celgene Performed in 2Q17 Market Realist
11:18AM  Exelixis, Inc. Continued Its Winning Ways and Rose 10% in July Thanks to These 3 Catalysts Motley Fool
10:48AM  Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up Zacks
08:01AM  IHS Markit Score Update: Decline in perceived credit worthiness is a negative sign for Bristol-Myers Squibb Co shares Markit
Aug-08-17 01:43PM  Retail names soar on earnings CNBC Videos
Aug-07-17 09:45AM  Q2 Earnings Fail to Impress Pharma ETF Zacks
Aug-06-17 10:37AM  AbbVies new, cheaper hepatitis C drug could launch the drug worlds own Hunger Games MarketWatch
08:21AM  10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year Motley Fool
Aug-04-17 07:40PM  [$$] Atlas Venture Scores Hat Trick of Early-Stage Biotech Exits The Wall Street Journal
05:04PM  Celgene vs. Gilead Sciences: Who Reported Better Earnings? Motley Fool
08:47AM  Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals Zacks
Aug-03-17 05:14PM  Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline Reuters
04:14PM  Bristol-Myers to buy IFM Therapeutics for $300 million, and potential contingent payments MarketWatch
04:03PM  Innately Innovative: IFM Therapeutics Acquired By BMS Forbes
04:00PM  Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy Business Insider
04:00PM  Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity Business Wire
Aug-02-17 03:06PM  Forget BMY's Q2 Earnings, Watch Out For Opdivo Trials Going Forward Forbes
11:12AM  The Zacks Analyst Blog Highlights: Procter & Gamble, Altria, Bristol-Myers, ConocoPhillips and Electronic Arts Zacks
09:20AM  What's in the Cards for Celldex (CLDX) this Earnings Season? Zacks
07:37AM  How BMY Is Valued following Its 2Q17 Earnings Market Realist
07:35AM  Eli Lillys Valuation after 2Q17 Earnings Release Market Realist
Aug-01-17 09:31PM  Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo Motley Fool
06:26PM  Top Stock Reports for Procter & Gamble, Altria & Bristol-Myers Zacks
01:35PM  Pfizer delays major M&A as it awaits U.S. tax reform clarity Reuters
11:35AM  Biotech Stocks Seen Fueled by Next M&A Wave Investopedia
10:39AM  Bristol-Myers Squibbs 2Q17 Earnings: Orencia and Other Brands Market Realist
09:10AM  Bristol-Myers Squibbs 2Q17 Earnings: Eliquis Market Realist
07:41AM  Bristol-Myers Squibbs 2Q17 Earnings: Virology Products Market Realist
07:29AM  Key FDA Events to Watch Out for in Aug 2017 Zacks
06:59AM  Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinotecan Business Wire
Jul-31-17 06:05PM  Bristol-Myers Squibbs 2Q17 Earnings: Opdivo Market Realist
04:51PM  Why Clovis Oncology Tumbled 13.5% Today Motley Fool
04:36PM  Examining Bristol-Myers Squibbs Oncology Portfolios 2Q17 Market Realist
04:30PM  Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today Motley Fool
04:15PM  How Dow's Merck Is Benefiting On The Backs On AstraZeneca, Bristol Investor's Business Daily
04:11PM  Why Clovis, Regeneron Are Leading A Biotech Deluge Today Investor's Business Daily
02:38PM  Bristol-Myers Squibb Reports Growth in 2Q17 Market Realist
01:45PM  Clovis Sell-Off May Be Overdone TheStreet.com
12:49PM  A Beat From Qiagen NV, but Only Half a Raise Motley Fool
12:20PM  Pfizer Inc. (PFE) Stock Isnt the Sexiest, But its Worth Checking Out InvestorPlace
08:06AM  Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More Zacks
07:10AM  Bristol-Myers and Clovis will partner for cancer combination trials MarketWatch
06:59AM  Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types Business Wire
Jul-28-17 12:02PM  Bristol-Myers Squibb Co. :BMY-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
10:11AM  Company News For July 28, 2017 Zacks
09:46AM  Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : July 28, 2017 Capital Cube
07:10AM  Featured Company News - The European Commission Approves Bristol-Myers Squibb's ORENCIA(R) for the Treatment of Active Psoriatic Arthritis ACCESSWIRE
02:03AM  [$$] AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk The Wall Street Journal
01:24AM  Bristol-Myers beats Street 2Q forecasts Associated Press
Jul-27-17 04:18PM  Why AstraZeneca plc (ADR) (AZN), Advanced Micro Devices, Inc. (AMD) and Spirit Airlines Incorporated (SAVE) Are 3 of Todays Worst Stocks InvestorPlace
04:10PM  With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too TheStreet.com
03:12PM  AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers TheStreet.com
01:26PM  Did the Checkpoint Inhibitor Bubble Just Burst? Motley Fool
12:45PM  Why Bristol-Myers Squibb Co (BMY) Shares Are Sinking Today InvestorPlace
12:43PM  Bristol-Myers shares slump after failed AstraZeneca drug trial Reuters
11:07AM  Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View Zacks
10:27AM  AstraZeneca Beats, But Stock Dives On Drug Failure; 4 More Report Investor's Business Daily
10:12AM  [$$] AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk The Wall Street Journal
10:07AM  Gilead Sciences, Inc. (GILD) Stock Has Tremendous Potential Even Post-Rally InvestorPlace
09:55AM  Why Bristol-Myers is Tanking Barrons.com
09:12AM  AstraZeneca shares take historic tumble on failed lung cancer study CNBC
08:43AM  AstraZenecas late-stage trial failure sends its shares down 16% and Bristol-Myers, Merck stocks seesawing MarketWatch
08:40AM  Investor Network: Bristol-Myers Squibb Company to Host Earnings Call ACCESSWIRE
08:29AM  Morning Movers: Bristol-Myers Sinks, Barrick Climbs, Alexion Soars Barrons.com
08:07AM  AstraZeneca shares plummet 16% on late-stage trial failure; Bristol-Myers shares fall 6% and Merck shares rise 5% MarketWatch
07:22AM  Bristol-Myers reports Q2 profit match, revenue beat MarketWatch
07:15AM  Bristol-Myers (BMY) Q2 Earnings Beats Estimates Zacks
06:59AM  Bristol-Myers Squibb Reports Second Quarter Financial Results Business Wire
06:59AM  Bristol-Myers quarterly sales meet Wall Street estimates Reuters
06:42AM  The Fed Hints at Pausing Interest Rate Hikes, and That's a Good Thing: Market Recon TheStreet.com
Jul-26-17 09:23PM  Cancer drug war heats up as Big Pharma squares off against Genentech American City Business Journals
06:06PM  Analysts Recommendations for Bristol-Myers Squibb in 2Q17 Market Realist
04:35PM  Bristol-Myers Squibbs 2Q17 Estimates: Expect Growth! Market Realist
02:38PM  Bristol-Myers Squibbs 2Q17 Earnings: Analysts Estimates Market Realist
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaboration agreements with Portola Pharmaceuticals, Inc., Apexigen, Inc., and Nordic Bioscience; clinical research collaborations with Array BioPharma, Novartis, and Clovis Oncology, Inc.; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuels Theodore R. IIDirectorAug 02Buy55.946,000335,62218,000Aug 03 05:08 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510028,751Aug 03 05:07 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerMay 14Option Exercise0.0014,551014,551Jun 08 04:51 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400180,458May 09 04:32 PM
ANDREOTTI LAMBERTODirectorApr 07Sale53.2217,000904,791935,571Apr 10 05:09 PM
ANDREOTTI LAMBERTODirectorApr 06Sale53.2917,000905,964952,571Apr 10 05:09 PM
JUDGE ANN POWELLSVP, Global Human ResourcesApr 01Option Exercise0.001,554044,125Apr 04 07:17 PM
ANDREOTTI LAMBERTODirectorMar 28Sale56.2017,000955,369969,112Mar 29 06:19 PM
ANDREOTTI LAMBERTODirectorMar 27Sale56.1417,000954,451986,112Mar 29 06:19 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 17Sale56.495,000282,47021,483Mar 21 04:35 PM
Caldarella Joseph CSVP & ControllerMar 15Sale57.298,096463,77955,637Mar 22 06:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 14Sale56.7515,000851,22026,483Mar 16 04:37 PM
Caforio GiovanniChief Executive OfficerMar 10Option Exercise0.0087,6040199,229Mar 14 08:32 PM
Blin EmmanuelSVP, Chief Strategy OfficerMar 10Option Exercise0.0013,275023,690Mar 14 08:32 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.0066,7260346,770Mar 14 08:33 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0065,4240451,862Mar 14 08:33 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,7210119,772Mar 14 08:31 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0025,592035,898Mar 14 08:31 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0087,3240289,293Mar 14 08:31 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.0013,696041,215Mar 14 08:30 PM
ANDREOTTI LAMBERTODirectorMar 10Option Exercise0.00102,17401,060,105Mar 14 08:30 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0031,513052,546Mar 14 08:29 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0018,799073,284Mar 14 08:29 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0033,271051,898Mar 14 08:30 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.0015,484068,911Mar 14 08:29 PM
LEUNG SANDRAEVP, General CounselMar 06Sale57.0292,4055,268,563395,658Mar 07 04:39 PM
LEUNG SANDRAEVP, General CounselMar 03Option Exercise27.01116,1003,135,861488,063Mar 07 04:39 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 28Option Exercise27.0122,598610,372212,516Mar 01 04:47 PM
Samuels Theodore R. IIDirectorFeb 27Buy56.7712,000681,24012,000Mar 01 04:47 PM
ANDREOTTI LAMBERTODirectorJan 30Option Exercise27.01100,0002,701,000957,931Feb 01 04:43 PM
Elicker John ESVP, Public Affairs & IRJan 03Option Exercise0.00950056,232Jan 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4030192,801Dec 06 04:42 PM
Bancroft Charles AEVP & Chief Financial OfficerNov 01Option Exercise0.003,1000187,794Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorNov 01Option Exercise22.14305,9096,772,825998,777Nov 03 05:22 PM
Elicker John ESVP, Public Affairs & IRNov 01Option Exercise0.00494055,505Nov 03 05:21 PM
ANDREOTTI LAMBERTODirectorOct 11Option Exercise17.51368,7066,456,042692,868Oct 13 05:00 PM
ANDREOTTI LAMBERTODirectorSep 08Sale56.9710,800615,276323,699Sep 09 04:41 PM
ANDREOTTI LAMBERTODirectorSep 07Sale56.7710,800613,116334,499Sep 09 04:41 PM
Nielsen AnneChief Compliance & Ethics OffSep 03Option Exercise0.001,596029,722Sep 07 04:33 PM
ANDREOTTI LAMBERTODirectorAug 25Sale58.9211,600683,472345,299Aug 25 05:10 PM
ANDREOTTI LAMBERTODirectorAug 24Sale59.4311,600689,359356,899Aug 25 05:10 PM